Duane Peters from the Lupus Foundation of America interviews Francisca Lambert-Fliszar and Dr Evelyne Vinet from McGill University Health Centre in Canada. They discuss monitoring 6-mercaptopurine (6-MP) metabolite levels to enable personalisation of immunosuppressive therapies prior to conception or during pregnancy, in order to most effectively and safely control the disease during this critical time.
Access the paper here: https://lupus.bmj.com/content/8/1/e000519
Podden och tillhörande omslagsbild på den här sidan tillhör BMJ Group. Innehållet i podden är skapat av BMJ Group och inte av, eller tillsammans med, Poddtoppen.
